Suphot Srimuninnimit

Suphot Srimuninnimit, MD is Professor of Medical Oncology and Head of the Division of Medical Oncology at Siriraj Hospital, Thailand's largest and most prestigious academic medical center at Mahidol University. His career has centered on improving cancer outcomes in Thailand and the broader Southeast Asian region, where cancer incidence is rising rapidly but healthcare resources remain constrained relative to the burden. He is recognized as a leading authority on EGFR-mutant non-small cell lung cancer in Asian populations, a critical area given that EGFR mutation rates in Asian lung adenocarcinoma patients (~50%) are dramatically higher than in Western patients (~15%), making targeted therapy access a profound equity issue for the region. Dr. Srimuninnimit has led pivotal clinical trials of first- and second-generation EGFR tyrosine kinase inhibitors in Thai and Southeast Asian patients, and his advocacy for including generic versions of essential oncology medications on the Thai National List of Essential Medicines has expanded access to targeted therapies for tens of thousands of patients who could not otherwise afford originator-brand pricing. He chairs the ASEAN Oncology Society working group on cancer access and has contributed to UICC initiatives on improving affordable access to essential cancer medicines across the ASEAN region. His work on pragmatic treatment adaptations for resource-limited settings—including optimized monitoring schedules and cost-effective diagnostic pathways for molecular testing—has been widely adopted across the region. He has mentored over 100 oncology trainees from Thailand, Laos, Cambodia, Myanmar, and Vietnam.